Adults aged 18 and over with a diagnosis of atopic dermatitis (AD) that has been present for at least 6 months, are needed for a research trial. To qualify for the study, individuals must have moderate to severe eczema with involvement of 10% or more body surface area (BSA), and a history of inadequate response to topical corticosteroids (TCS) of medium to higher potency within 6 months, or for whom topical treatments are otherwise medically inadvisable.
Participants will receive an investigational medication (active study drug) or placebo via injection. Study medication and study-related assessments will be provided at no cost. Reimbursement for study-related expenses will be provided.
Study participation will last about 40 weeks and involve about 11 visits to the study centre.
Washington, D.C. - Foxhall Research Center
Carlton - Skin Health Institute
Windsor - XLR8 Medical Research
Toronto - Research Toronto
Richmond Hill - The Centre for Dermatology
Peterborough - SKiN Centre for Dermatology
Oakville - The Centre for Clinical Trials
Markham - Lynderm Research Inc.
Etobicoke - Kingsway Clinical Research
Surrey - Dr. Chih-ho Hong Medical Inc.
Calgary - Beacon Dermatology
Similar Trials
No Similar Trials FoundThe following information is from ClinicalTrials.gov
Last Update Posted: September 24, 2023
NCT05651711
Amgen
Brief Summary:
The co-primary objectives of the study are to: Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD). Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Eczema Area and Severity Index (EASI).
Condition or Disease:
Atopic Dermatitis
Intervention/Treatment:
Drug: RocatinlimabPhase:
Phase 3
Ages Eligible for Study:
18 Years and 100 Years (Adult)
Sexes Eligible for Study:
All
Inclusion Criteria:
Age ≥ 18 years (or ≥ legal adult age within the country if it is older than 18 years at signing of informed consent) with a diagnosis of AD according to the AAD Consensus Criteria (2014) present for at least 12 months
History of inadequate response to TCS (Topical Corticosteroid) of medium or higher potency (with or without topical calcineurin inhibitors [TCI]) as appropriate or for whom topical treatments are otherwise medically inadvisable (eg, because of important side effects or safety risks).
EASI score ≥16
vIGA-AD score ≥3
≥10% body surface area (BSA) of AD involvement
Worst pruritus numerical rating scale ≥ 4
Exclusion Criteria:
Treatment with a biological product within 12 weeks or 5 half-lives, whichever is longer, prior to Day 1
Treatment with any of the following medications or therapies within 4 weeks or 5 half-lives, whichever is longer, prior to Day 1:
Systemic corticosteroids
Systemic immunosuppressants
Oral or topical Janus kinase inhibitors
Treatment with any of the following medications or therapies within 1 week, prior to Day 1:
TCS of any potency
TCI
Topical phosphodiesterase type 4 inhibitors
Other topical immunosuppressive agents
Phototherapy
Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.
register now